secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001528287-22-000011
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q1 revenue $11.4M, net loss widens to $11.5M; guides FY2022 revenue $45-48M
--------------------------------------------------------------------------------

- Total revenue $11.4M (+2% YoY); initial implant rev $8.8M (+9%); replacement rev $2.6M (-16%).
- Net loss widened to $11.5M from $8.8M; operating expenses $18.0M vs $12.4M.
- Gross margin 73% vs 76% due to higher costs and COVID disruptions; cash $103.2M.
- FY2022 guidance: revenue $45-48M, initial implants $39-42M, opex $74-76M.
- On track to enroll first patients in NAUTILUS trial for generalized epilepsy expansion mid-2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000011/0001528287-22-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000011/npce-20220512.htm
  HTML page:      https://secwatch.observer/filing/0001528287-22-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer